159 related articles for article (PubMed ID: 38110365)
1. Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer.
Liu X; Zhang X; Shao Z; Zhong X; Ding X; Wu L; Chen J; He P; Cheng Y; Zhu K; Zheng D; Jing J; Luo T
Signal Transduct Target Ther; 2023 Dec; 8(1):463. PubMed ID: 38110365
[TBL] [Abstract][Full Text] [Related]
2. P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer.
Chen H; Si Y; Wen J; Hu C; Xia E; Wang Y; Wang O
Neoplasia; 2023 Sep; 43():100913. PubMed ID: 37348428
[TBL] [Abstract][Full Text] [Related]
3. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.
Su B; Huang T; Jin Y; Yin H; Qiu H; Yuan X
Gastric Cancer; 2021 Mar; 24(2):352-367. PubMed ID: 33030616
[TBL] [Abstract][Full Text] [Related]
4. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
[TBL] [Abstract][Full Text] [Related]
5. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
[TBL] [Abstract][Full Text] [Related]
7. Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.
Huang T; Luo X; Wu B; Peng P; Dai Y; Hu G; Qiu H; Yuan X
Oncol Rep; 2020 Dec; 44(6):2634-2644. PubMed ID: 33125154
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
9. Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.
Ma X; Li Y; Zhao Z; Li L; Gao C; Liu D; Li B; Zhao B
Exp Biol Med (Maywood); 2023 Jan; 248(2):106-116. PubMed ID: 36533572
[TBL] [Abstract][Full Text] [Related]
10. The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer.
Wang Y; Yuan X; Li J; Liu Z; Li X; Wang Z; Wei L; Li Y; Wang X
Front Cell Dev Biol; 2021; 9():785796. PubMed ID: 34977029
[TBL] [Abstract][Full Text] [Related]
11. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
12. Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2
Bu J; Zhang Y; Niu N; Bi K; Sun L; Qiao X; Wang Y; Zhang Y; Jiang X; Wang D; Ma Q; Li H; Liu C
Elife; 2023 Jan; 12():. PubMed ID: 36602226
[TBL] [Abstract][Full Text] [Related]
13. Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2
Yi J; Chen S; Yi P; Luo J; Fang M; Du Y; Zou L; Fan P
Oncol Res; 2020 Dec; 28(5):519-531. PubMed ID: 32727638
[TBL] [Abstract][Full Text] [Related]
14. Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer.
Niu Q; Liu J; Huang T; Su B; Zhang Y; Yuan X
Oncol Res Treat; 2023; 46(1-2):11-25. PubMed ID: 36481773
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.
Wang N; Li L; Xiong Y; Chi J; Liu X; Zhong C; Wang F; Gu Y
Front Oncol; 2021; 11():729212. PubMed ID: 34976791
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial.
Wang W; Zhang J; Chang JY; Yao DS; Hu F; Liang YP; Shen Y; Liu YQ; Qi HH; Tong JB; Cai HF
Gland Surg; 2023 Feb; 12(2):208-214. PubMed ID: 36915823
[TBL] [Abstract][Full Text] [Related]
17. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
Zhu W; Wu J; Cui M; Zhang L
Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
[TBL] [Abstract][Full Text] [Related]
18. Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations.
Tian H; Qu M; Zhang G; Yuan L; Shi Q; Wang Y; Yang Y; Zhang Y; Qi X
Oncologist; 2023 Jul; 28(7):e534-e541. PubMed ID: 37120151
[TBL] [Abstract][Full Text] [Related]
19. MiR-18a-5p attenuates HER2-positive breast cancer development by regulating PI3K/AKT pathway.
Liu Y; Yang H
Cancer Biol Ther; 2023 Dec; 24(1):2224512. PubMed ID: 37394766
[TBL] [Abstract][Full Text] [Related]
20. Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study.
Hao L; Dong J; Yu H; Chen J; Han X; Pan Y
Transl Cancer Res; 2023 Oct; 12(10):2726-2741. PubMed ID: 37969380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
